Authors

• Atbin Djamshidian (ORCID: https://orcid.org/0000-0001-7174-6000)
• Astrid Grams (ORCID: https://orcid.org/0000-0003-2304-3946)
• Bernadette Wimmer
• Katarína Schwarzová (ORCID: https://orcid.org/0009-0006-0350-7861)
• Greta Hemicker
• Florian Krismer (ORCID: https://orcid.org/0000-0002-4493-5073)
• Beatrice Heim (ORCID: https://orcid.org/0000-0002-6749-3044)
• Marina Peball (ORCID: https://orcid.org/0000-0002-0791-7300)
• Klaus Seppi (ORCID: https://orcid.org/0000-0001-6503-1455)
• Philipp Mahlknecht (ORCID: https://orcid.org/0000-0003-0671-0516)
• Federico Carbone (ORCID: https://orcid.org/0000-0002-6909-0150)
• Samuel Labrecque
• Clancy Cerejo

Institutions

• Innsbruck Medical University (AT)
• Universität Innsbruck (AT)
• University of Applied Sciences Kufstein (AT)

Publication Details

Journal

Movement Disorders

Published

2025-09-22

DOI

https://doi.org/10.1002/mds.70059

Primary Topic

Genetic Neurodegenerative Diseases

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Michael J. Fox Foundation for Parkinson's Research
• Novartis
• Sanofi
• Teva Pharmaceutical Industries
• International Parkinson and Movement Disorder Society
• Ionis Pharmaceuticals
• Austrian Science Fund
• Novo Nordisk
• H. Lundbeck A/S
• AOP Orphan
• National Institutes of Health